Baptist Gallwitz

3.4k total citations · 1 hit paper
87 papers, 2.4k citations indexed

About

Baptist Gallwitz is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Genetics. According to data from OpenAlex, Baptist Gallwitz has authored 87 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Molecular Biology and 23 papers in Genetics. Recurrent topics in Baptist Gallwitz's work include Diabetes Treatment and Management (54 papers), Diabetes Management and Research (31 papers) and Metabolism, Diabetes, and Cancer (24 papers). Baptist Gallwitz is often cited by papers focused on Diabetes Treatment and Management (54 papers), Diabetes Management and Research (31 papers) and Metabolism, Diabetes, and Cancer (24 papers). Baptist Gallwitz collaborates with scholars based in Germany, United States and United Kingdom. Baptist Gallwitz's co-authors include Wolfgang E. Schmidt, Rolf Mentlein, Maximilian von Eynatten, Julio Rosenstock, Sanjay Patel, Klaus A. Dugi, T. Rauch, Hans‐Juergen Woerle, Sudipta Bhattacharya and Erhard Siegel and has published in prestigious journals such as The Lancet, PLoS ONE and Diabetes Care.

In The Last Decade

Baptist Gallwitz

69 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1993 966 citations Rolf Mentlein, Baptist Gallwitz et al. European Journal of Biochemistry profile →

Peers

Countries citing papers authored by Baptist Gallwitz

Since Specialization

Citations

This map shows the geographic impact of Baptist Gallwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baptist Gallwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baptist Gallwitz more than expected).

Fields of papers citing papers by Baptist Gallwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baptist Gallwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baptist Gallwitz. The network helps show where Baptist Gallwitz may publish in the future.

Co-authorship network of co-authors of Baptist Gallwitz

This figure shows the co-authorship network connecting the top 25 collaborators of Baptist Gallwitz. A scholar is included among the top collaborators of Baptist Gallwitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baptist Gallwitz. Baptist Gallwitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diabetes im Krankenhaus 2025 ·Karsten Müssig, Baptist Gallwitz, Thomas Haak, Monika Kellerer, Erhard Siegel	0
2	Diabetes im Krankenhaus 2024 ·Diabetologie und Stoffwechsel ·Karsten Müssig, Baptist Gallwitz, Thomas Haak, Monika Kellerer, Erhard Siegel	0
3	Diabetes im Krankenhaus 2024 ·Diabetologie und Stoffwechsel ·Karsten Müssig, Baptist Gallwitz, Thomas Haak, Monika Kellerer, Erhard Siegel	1
4	Therapy of Type 2 Diabetes 2024 ·Experimental and Clinical Endocrinology & Diabetes ·Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller‐Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel	1
5	Therapie des Typ-2-Diabetes 2024 ·Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller‐Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel	0
6	Patients with Type 2 Diabetes Reach Glycaemic Targets Faster with Tirzepatide Compared to Semaglutide and Titrated Insulin Degludec 2023 ·Diabetologie und Stoffwechsel ·Adie Viljoen, Kevin M. Pantalone, Rodolfo J. Galindo, Xuewei Cui, Ruth Huh, Laura Fernández Landó, (unknown), Baptist Gallwitz	0
7	Clinical Use of DPP-4 Inhibitors 2019 ·Frontiers in Endocrinology ·Baptist Gallwitz	238
8	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial 2017 ·Journal of Diabetes Investigation ·Ronald C.W., Stefano Del Prato, Baptist Gallwitz, Vyankatesh Shivane, Diane J. Lewis-D’Agostino, Zelie Bailes, Sanjay Patel, Jisoo Lee, Maximilian von Eynatten, (unknown), Stuart A. Ross	11
9	DPP4 gene variation affects GLP-1 secretion, insulin secretion, and glucose tolerance in humans with high body adiposity 2017 ·PLoS ONE ·Anja Böhm, Róbert Wágner, Fausto Machicao, Jens J. Holst, Baptist Gallwitz, Norbert Stefan, Andreas Fritsche, Hans‐Ulrich Häring, Harald Staiger	16
10	Praxisempfehlungen DDG/DGIM : Therapie des Typ-2-Diabetes 2013 ·Diabetologie und Stoffwechsel ·R. Landgraf, Monika Kellerer, (unknown), Baptist Gallwitz, A. Hamann, Hans‐Georg Joost, H. H. Klein, (unknown), Michael A. Nauck, (unknown), Stefanie Schreiber, Erhard Siegel, S. Matthäei	6
11	2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial 2012 ·The Lancet ·Baptist Gallwitz, Julio Rosenstock, T. Rauch, Sudipta Bhattacharya, Sanjay Patel, Maximilian von Eynatten, Klaus A. Dugi, Hans‐Juergen Woerle	277
12	Neue Ansätze in der Therapie des Typ-2-Diabetes 2010 ·MMW - Fortschritte der Medizin ·Baptist Gallwitz	4
13	Bedeutung von GLP‐1 für die Glucose‐Homöostase. Entdeckung der Inkretine 2010 ·Pharmazie in unserer Zeit ·Henning Blume, Ralph‐Steven Wedemeyer, Baptist Gallwitz	1
14	Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time 2009 ·International Journal of Clinical Practice ·Baptist Gallwitz, Allan Vaag, A Falahati, Sten Madsbad	50
15	The European Exenatide study of long‐term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics 2009 ·Diabetes Obesity and Metabolism ·Christof Kazda, Baptist Gallwitz, Rafael Simó, Juan Rosas Guzmán, Petra Kraus, Claudia Nicolay, Ludger Rose, Guntram Schernthaner	5
16	The Fate of Beta-Cells in Type 2 Diabetes and the Possible Role of Pharmacological Interventions 2006 ·The Review of Diabetic Studies ·Baptist Gallwitz	11
17	Hashimoto's encephalopathy presenting with bipolar affective disorder 2005 ·Bipolar Disorders ·Karsten Müssig, M. Bartels, Baptist Gallwitz, Dirk Leube, Hans‐Ulrich Häring, Tilo Kircher	29
18	GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro 2000 ·Regulatory Peptides ·Baptist Gallwitz, (unknown), Corinna Morys‐Wortmann, Rolf Mentlein, Erhard Siegel, Wolfgang E. Schmidt	55
19	Biological activity of GLP-1-analogues with N-terminal modifications 1999 ·Regulatory Peptides ·Erhard Siegel, Baptist Gallwitz, (unknown), Rolf Mentlein, Corinna Morys‐Wortmann, Ulrich R. Fölsch, (unknown), Karsten Drescher, Wolfgang E. Schmidt	75
20	Structure/Activity Characterization of Glucagon‐Like Peptide‐1 1994 ·European Journal of Biochemistry ·Baptist Gallwitz, M Witt, (unknown), Corinna Morys‐Wortmann, Bodo Zimmermann, Klaus Eckart, Ulrich R. Fölsch, Wolfgang E. Schmidt	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact